Everolimus has been approved for the treatment of pancreatic neuroendocrine tumors (p-NETs), advanced renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC), and in combination with exemestane for advanced hormone-receptor (HR)-positive, HER2-negative breast cancer [31,32]. The gene discussed is ERBB2; the disease is tuberous sclerosis.